This week’s Neuroscience update highlights regulatory progress, clinical readouts, device-enabled care, neuroimmune research, and platform advances.
In Today’s Newsletter
Dive deeper
🧠 Teva to acquire Emalex, adding ecopipam for pediatric Tourette syndrome [1] [US • 29 Apr 2026]
https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-AcquireEmalexBiosciences-Adding-NDA-Ready-First-in-Class-Therapy-to-Neuroscience-Pipeline-and-Accelerating-Tevas-Pivot-to-Growth-Strategy/default.aspx
Context: Ecopipam (Emalex; selective dopamine D1 receptor antagonist) is NDA-ready for pediatric Tourette syndrome. Key point: Teva will acquire Emalex for $700 million upfront, with up to $200 million in milestones and royalties. Implication: Signals pipeline investment and modality expansion.
🧪 ABBV-932 Phase 2 bipolar depression update from Gedeon Richter [2] [29 Apr 2026]
https://www.gedeonrichter.com/en/news/260429_2
Context: ABBV-932 (RGH-932) was tested in a 6-week exploratory Phase 2 trial in 161 patients with bipolar depression.
Key point: The overall MADRS difference versus placebo was not statistically significant, with a signal in a bipolar 1 subgroup.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Denovo receives US patent for DGM4 biomarker in DB104 program [3] [US • 29 Apr 2026]
https://www.manilatimes.net/2026/04/29/tmt-newswire/globenewswire/denovo-announces-issuance-of-us-patent-of-novel-genetic-biomarker-ank3-dgm4-for-liafensine-db104/2331363
Context: DGM4 (ANK3; Denovo Genomic Marker platform) is linked to DB104 (liafensine) in treatment-resistant depression.
Key point: Denovo received US patent 12,612,261, extending DB104 biomarker IP protection until at least 2043.
Implication: Signals pipeline investment and modality expansion.
⚡ Hinge Health launches Migraine Care Program with Enso device [4] [US • 29 Apr 2026]
https://www.businesswire.com/news/home/20260429087251/en/Hinge-Health-launches-comprehensive-Migraine-Care-Program
Context: Hinge Health’s Enso device is FDA-cleared for migraine and the program is scheduled to roll out in May 2026.
Key point: The Migraine Care Program combines drug-free pain relief, trigger tracking, and prevention support.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🧠 SetPoint enrolls first patients in RRMS neuroimmune modulation study [5] [US • 30 Apr 2026]
https://setpointmedical.com/setpoint-medical-announces-first-patients-enrolled-in-pilot-study-evaluating-neuroimmune-modulation-for-multiple-sclerosis/
Context: SetPoint System is an implanted vagus nerve stimulation device studied as adjunctive therapy in RRMS.
Key point: SetPoint enrolled first patients in a randomized, sham-controlled, double-blind pilot study of up to 60 adults.
Implication: May influence prescriber choice and payer reviews pending full data.
🧩 Health Canada approves Kisunla for early Alzheimer’s disease [6] [Canada • 04 May 2026]
https://www.theglobeandmail.com/canada/article-health-canada-approves-second-drug-targeting-underlying-cause-of/
Context: Kisunla (donanemab; Eli Lilly Canada) is a once-monthly IV amyloid-targeting therapy for early Alzheimer’s disease.
Key point: Health Canada approved donanemab for mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Implication: May influence prescriber choice and payer reviews pending full data.
💊 FDA approves AUVELITY for Alzheimer’s disease agitation [7] [US • 30 Apr 2026]
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-approval-auvelityr
Context: AUVELITY (Axsome; dextromethorphan HBr and bupropion HCl) targets NMDA and sigma-1 receptors.
Key point: FDA approved AUVELITY for agitation associated with dementia due to Alzheimer’s disease.
Implication: May influence prescriber choice and payer reviews pending full data.
📊 Neurocrine survey highlights TD employment burden [8] [US • 05 May 2026]
https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-new-survey-results-showing
Context: Ipsos surveyed 100 US respondents for Neurocrine, including 70 adults diagnosed with tardive dyskinesia.
Key point: About one in five surveyed working adults with TD reported quitting a job due to symptoms before treatment.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🧬 Quiver receives NIH HEAL award for Nav1.7 ASO pain therapy [9] [US • 04 May 2026]
https://www.businesswire.com/news/home/20260504940465/en/Quiver-Bioscience-Receives-NIH-HEAL-Initiative-Award-to-Advance-Nav1.7-Antisense-Therapy-for-Chronic-Pain-Through-Early-Clinical-Trials
Context: QV-2421 (Quiver; Nav1.7-targeted ASO) is being developed for chronic neuropathic pain.
Key point: NIH HEAL awarded up to $9.3 million in direct funding, with potential development support of about $20 million.
Implication: Signals pipeline investment and modality expansion.
Why it Matters
- CNS dealmaking remains active, with Teva adding an NDA-ready Tourette syndrome asset through Emalex. [1]
- Alzheimer’s disease treatment options expanded across both disease modification and agitation management. [6], [7]
- Precision and platform approaches are moving forward in depression and chronic pain through biomarker and ASO strategies. [3], [9]
- Device-enabled neuromodulation continues to enter CNS and autoimmune-adjacent indications such as RRMS and migraine. [4], [5]
- Real-world burden data remain important for conditions where symptoms affect work, caregiving, and daily function. [8]
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Neuroscience archive on our research hub page.
FAQ
What is Teva acquiring from Emalex Biosciences?
Teva is acquiring Emalex and its lead asset ecopipam, an NDA-ready selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The NDA submission is anticipated in 2H 2026. [1]
What happened in Gedeon Richter’s ABBV-932 Phase 2 bipolar depression study?
ABBV-932 did not show a statistically significant overall difference versus placebo on MADRS total score. A pre-specified bipolar 1 subgroup showed an efficacy signal. [2]
What is Denovo’s DGM4 patent tied to?
Denovo’s US patent covers use of the DGM4 genetic biomarker for the DB104 (liafensine) treatment-resistant depression program. The company says protection extends until at least 2043. [3]
What did FDA approve for Axsome’s AUVELITY?
FDA approved AUVELITY for agitation associated with dementia due to Alzheimer’s disease. The approval was supported by the ADVANCE-1 and ACCORD-2 studies. [7]
What did Health Canada approve for Eli Lilly Canada?
Health Canada approved Kisunla (donanemab), a once-monthly IV therapy for mild cognitive impairment or mild dementia due to Alzheimer’s disease. [6]
What is Quiver Bioscience advancing with NIH HEAL support?
Quiver is advancing QV-2421, a Nav1.7-targeted antisense oligonucleotide for chronic neuropathic pain, through IND-enabling work and potential first-in-human trials. [9]
Entities / Keywords
Teva Pharmaceutical Industries, Teva Pharmaceuticals, Emalex Biosciences, Paragon Biosciences, ecopipam, Tourette syndrome, dopamine D1 receptor antagonist
Gedeon Richter, AbbVie, ABBV-932, RGH-932, bipolar depression, bipolar 1 depression, MADRS
Denovo Biopharma, DB104, liafensine, DGM4, ANK3, treatment-resistant depression, TRD
Hinge Health, Enso, Migraine Care Program, migraine, nerve stimulation, digital health
SetPoint Medical, SetPoint System, relapsing-remitting multiple sclerosis, RRMS, vagus nerve stimulation, remyelination
Eli Lilly Canada, Kisunla, donanemab, Alzheimer’s disease, beta-amyloid, mild cognitive impairment
Axsome Therapeutics, AUVELITY, dextromethorphan HBr, bupropion HCl, Alzheimer’s disease agitation, NMDA receptor, sigma-1 receptor
Neurocrine Biosciences, tardive dyskinesia, TD, VMAT2 inhibitor, Ipsos, employment burden
Quiver Bioscience, QV-2421, Nav1.7, antisense oligonucleotide, ASO, NIH HEAL Initiative, NINDS, chronic neuropathic pain
References
- https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-AcquireEmalexBiosciences-Adding-NDA-Ready-First-in-Class-Therapy-to-Neuroscience-Pipeline-and-Accelerating-Tevas-Pivot-to-Growth-Strategy/default.aspx
- https://www.gedeonrichter.com/en/news/260429_2
- https://www.manilatimes.net/2026/04/29/tmt-newswire/globenewswire/denovo-announces-issuance-of-us-patent-of-novel-genetic-biomarker-ank3-dgm4-for-liafensine-db104/2331363
- https://www.businesswire.com/news/home/20260429087251/en/Hinge-Health-launches-comprehensive-Migraine-Care-Program
- https://setpointmedical.com/setpoint-medical-announces-first-patients-enrolled-in-pilot-study-evaluating-neuroimmune-modulation-for-multiple-sclerosis/
- https://www.theglobeandmail.com/canada/article-health-canada-approves-second-drug-targeting-underlying-cause-of/
- https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-approval-auvelityr
- https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-new-survey-results-showing
- https://www.businesswire.com/news/home/20260504940465/en/Quiver-Bioscience-Receives-NIH-HEAL-Initiative-Award-to-Advance-Nav1.7-Antisense-Therapy-for-Chronic-Pain-Through-Early-Clinical-Trials